-+ 0.00%
-+ 0.00%
-+ 0.00%

Compass Pathways Announced That All Participants Have Completed Dosing In Part A Of The COMP005 Phase 3 Trial For Treatment-Resistant Depression; The Company Is On Track To Disclose Top-line 6-week Primary Endpoint Results In Late June

Benzinga·04/22/2025 10:11:05
Listen to the news

 Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo.